coulter/Corixa - neue Phase - neuer Thread - 500 Beiträge pro Seite

[toller]

hi rainrain und romeo66,

sieht so aus, als ob wir bald zum eingeschlafenen corixa thread wechseln...coulter wird nicht mehr gehandelt, meine bank weiss natuerlich nix von nem aktientausch...

bis dennn
toller

[Romeo66]

Corixa and CoPharma Collaborate to Develop and Commercialize Corixa`s Novel Cardioprotectant


01-17-01 08:04 AM EST | SEATTLE, and HOPKINTON, Mass. /PRNewswire/ -- Corixa Corporation (Nasdaq: CRXA), a research and development-based biotechnology company, and CoPharma, Inc., a Massachusetts-based integrated pharmaceutical development company, today announced a license, development and commercialization agreement for Corixa`s cardioprotectant, RC.552(TM). Under the terms of the agreement, CoPharma will develop and commercialize Corixa`s RC.552 for the treatment and prevention of cardiac disorders, neuronal damage and ischemia- reperfusion injuries.

The agreement provides CoPharma with exclusive rights to develop and market RC.552 in the licensed indications in the United States, Canada, Japan, Australia and New Zealand, as well as certain other countries in Asia, the Middle East and Africa. CoPharma will manage product development, including clinical trials and regulatory submissions and have an option for product manufacturing. CoPharma will pay Corixa a license fee, success-based milestone payments and a combination of royalties and profit-share in the event of CoPharma product sales. The collaboration will be overseen by a joint steering committee made up of representatives from both companies. Further details of the agreement were not disclosed by either party.

RC.552 is a member of a family of compounds called aminoalkyl glucosaminide 4-phosphates or AGPs, which exert marked biological effects on a variety of cells and tissues. AGPs are the result of long-standing research and development activity on the part of the former Ribi Immunochem Research, Inc., a company acquired by Corixa in October 1999. RC.552 is believed to mediate its tissue-sparing protection from ischemic damage by inducing nitric oxide synthase. Other AGP molecules mediate distinct cellular effects. For example, Corixa`s RC-529(TM), now in Phase III clinical trials, functions as a potent vaccine adjuvant.

"We are pleased to be working with CoPharma to further the development of our novel cardioprotectant, RC.552(TM)," stated Steven Gillis, Ph.D., Chairman and Chief Executive Officer of Corixa. "We continue to be impressed with the potent preclinical bioactivity of multiple AGPs and are pleased with our progress in development and licensing of these molecules since our acquisition of Ribi Immunochem Research, Inc. Our relationship with CoPharma, together with initiation of RC-529 adjuvant Phase III clinical trials, are recent examples of the broad product potential of discrete members of the AGP family."

"This partnership with Corixa is a key component of our business strategy to develop early to mid-stage clinical compounds through innovative partnering arrangements," said Samuel K. Ackerman, MD, President and CEO of CoPharma. "RC.552 will be a major product in our growing portfolio of development-stage proprietary products in the fields of critical care, infectious disease and cancer. As shown in preclinical studies by numerous laboratories internationally, RC.552 appears to be a potent and nontoxic cardioprotectant that can prevent experimental cardiac damage in multiple animal species. As with other CoPharma products, a number of important clinical applications may be possible. We look forward to working with Corixa and to initiating clinical trials in the near future."


About RC.552

Ischemia-reperfusion injury is damage that can occur in tissue during the oxygen deprivation of interrupted blood flow, or ischemia, and when blood flow is restored after, for example, a heart attack or a planned event such as cardiovascular surgery, angioplasty or organ transplantation. Paradoxically, restoring blood flow to ischemic tissue may induce a complex series of events leading to both reversible and irreversible tissue damage beyond any damage that may have occurred during the ischemic period.

It is believed that a significant factor in reperfusion injury is the generation of free radical molecules, which attack and damage cardiac tissue. The injury can result in a number of complications, including tissue death, depression of heart function, irregular heartbeat and in some cases, death. Corixa`s synthetic chemistry program has generated a novel potential cardioprotectant, RC.552, which has demonstrated in preclinical studies to be fast acting and potent. Potential clinical applications for RC.552 cardioprotectant may include coronary artery bypass graft surgery, aortic valve replacement, angioplasty, non-cardiac surgery in high-risk patients, unstable angina, acute myocardial infarction, thrombolytic therapy, stroke and other CNS injury and organ transplantation.


About Corixa

Corixa is a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary vaccine components on a standalone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, Bexxar(TM), a monoclonal antibody conjugated to a radioisotope.

The company partners with numerous developers and marketers of pharmaceuticals and diagnostics, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. and South San Francisco, Calif. For more information, please visit Corixa`s website at www.corixa.com or call the company`s investor relations information line at 1.877.4CORIXA or 1.877.426.7492.


About CoPharma

CoPharma, Inc. is an integrated pharmaceutical development organization, created to respond to the growing disparity between the large number of newly discovered drugs and the pharmaceutical industry`s limited capacity to develop them. CoPharma targets development of early to mid-stage clinical compounds through in-licensing, joint ventures and novel partnership structures. CoPharma efficiently and cost-effectively advances proprietary small molecule and protein therapeutics through clinical and manufacturing development, concentrating resources on the principal value-generating step in the pharmaceutical commercialization chain. In addition to RC.552(TM), CoPharma has an anti-proliferative compound, PEN203, in Phase II testing for the treatment of basal cell carcinoma and psoriasis. CoPharma has licensed from a major Boston-based cancer research institute a cancer therapeutic, CO-501, for use in chemotherapy of breast, ovarian, colorectal, prostate and other cancers. CO-501 is targeted to enter clinical trials in 2001.

Based in Hopkinton, MA, CoPharma Inc. was founded in 1999 and has 70 employees. CoPharma operates a 65,000 sq. ft. cGMP FDA approved biomanufacturing facility for contract production of licensed and investigational biopharmaceuticals. CoPharma is privately held, and to date the company has been financed by $15 million from Ampersand Ventures, a leading venture capital firm. For further information on CoPharma and its programs, please contact, David Fanning, Chief Business Officer, CoPharma Inc. by e-mail at [e-mail] or by calling 508.435.8441.


Forward-Looking Statements

Except for the historical information presented, certain matters discussed in this press release are forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made. They are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that could affect Corixa`s actual results include, but are not limited to failure of RC 552 to prove useful in treating disease and the "Factors Affecting Our Operating Results, Our Business and Our Stock Price," described in our Quarterly Report on Form 10-Q/A filed on November 7, 2000 and our Registration Statement on Form S-4/A filed on November 17, 2000, copies of which are available on our Web site, www.corixa.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

[Ikarus]

Hey Toller immer noch investiert? Such etwas mehr Infos.
Corixa hat eine Pipeline die mehrer Produkt in allen Phasen hat. Der massive Kursrückgang kann doch nicht nur aus Sorge um Bexxar passiert sein, oder doch? Ich glaube sowieso dass Bexxar sich gegen IDEC durchsetzten kann.

Ist der Kursrutsch vielleicht auf die Übernahme von Coulter zurückzuführen?

[toller]

hi,

ja klar, immer noch inverstiert. hab eigentlich keine wirkliche erklärung für den absturz. Corixa´s pipeline ist gut gefüllt, und CRXA wird auch von einigen US-Analysten zu den ausichtsreichsten Bio´s gezählt.

verfolge manchmal das yahoo-board zu Corixa, da war mitzukriegen, dass die FDA irgendeinen offiziellen Termin abgesagt hat, weiss nicht mehr genau, jedenfalls soll dass die angst geschürt haben, bei BExxar stimmt was nicht, chance auf nicht-Zulassung.

mal sehen.

ich denke, selbst wenn bexxar nicht zugelassen wird, ist die auswirkung auf crxa nicht mehr so hoch, wie sie wäre wenn coulter noch eigenständig wäre. CLTR würde siche gegen 2$ gehen. crxa´s pipeline verhindert das.

grüße

[toller]

Tuesday February 13, 1:22 pm Eastern Time
German fund sees strong growth in biotech funds 2001
FRANKFURT, Feb 13 (Reuters) - DWS Investment, manager of one of the world`s biggest biotech funds, said on Tuesday it expects biotech firms worldwide to launch 25 new drugs this year, boosting both the firms` value and returns for investors.

In a report published on its web page (www.dws.de), the Deutsche Bank unit said it expects Enzon Inc. (NasdaqNM:ENZN - news), Tanox Inc. (NasdaqNM:TNOX - news), Corixa Corp. (NasdaqNM:CRXA - news), Praecis Pharmaceuticals Inc. (NasdaqNM:PRCS - news) Aviron (NasdaqNM:AVIR - news) and Imclone Systems Inc. (NasdaqNM:IMCL - news) to quadruple their value.

The companies are expected show average growth rates of 25 to 50 percent, after they win approval by the U.S. Food and Drug Administration (FDA) for their products.

``The fundamental data for biotechnology is better than ever and strong enough, to provoke a recovery in the sector,`` said Dws.

``Investors with patience and endurance, who invest in a diversified portfolio of biotech shares, can expect above-average returns.``

Germany`s Neuer Markt biotech index (^NMPA - news) rose 1.2 percent on Tuesday, outperforming the NEMAX 50`s 0.42 percent rise. The Neuer Markt biotech index has fallen 12.3 percent this year.

Qiagen NV , a Neuer Markt-listed provider of nucleic acid preparation kits, rose 4.7 percent to 38.51 euros.

DWS manages two biotech funds - Type O, which is worth 2.4 billion euros ($2.21 billion), and the SICAV fund, worth 260 million euros. It said some biotech firms have ample capital reserves to fund growth for more than 10 years, after the sector raised $33 billion on capital markets last year. DWS forecast an increased number partnerships between biotechs and pharmaceutical companies.

[toller]

nochmal zu obigem posting:

crxa scheint hier noch extrem weniger gehandelt zu werden als damals coulter. wahrscheinlich warten die ganzen coulter-aktionäre die entwicklung unter der flagge corixa erstmal ab.
jedenfalls sind vorgestern und auch heute mal etwas höhere (z.B. eine order über 1000 stück) Zahlen gehandelt worden,
als sonst.

Datum /erster/hoch/tief/letzer kurs/Volumen
14.02. 25,50 25,50 25,50 24,50 0,00 96
13.02. 24,50 25,80 24,50 25,80 0,00 1.343
12.02. 23,50 23,50 23,50 25,10 0,00 11
09.02. 0,00 0,00 0,00 23,75 0,00 0
08.02. 24,30 24,30 24,00 23,80 0,00 79
07.02. 25,00 25,00 25,00 24,30 0,00 103

dazu gibts auch wieder ne menge meldungen auf yahoo...im nächsten posting..

[milchdreamlover]

auf aktiencheck gibts glaub ich ne neue analysteneinschätzung

[toller]

Wednesday February 14, 4:55 pm Eastern Time
Psoriasis therapy shows benefit - Genesis
WELLINGTON, Feb 15 (Reuters) - A U.S. clinical trial of a New Zealand-developed therapy for the chronic skin disorder psoriasis had an appreciable clinical benefit, biotechnology company Genesis Research and Development Corp Ltd said on Thursday.

Genesis is developing the PVAC therapy in conjunction with Seattle-based Corixa Corporation (NasdaqNM:CRXA - news). The companies have signed commercialisation agreements with Medicis Pharmaceutical Corporation (NYSE:MRX - news) in the United States and Zenyaku Kogyo Co. Ltd in Japan.

``Analysis of the results of a four-arm, randomised, double-blinded, controlled study in the United States, suggests that PVAC therapy at a dose of 15 micrograms per injection provides appreciable clinical benefit in patients with moderate to severe psoriasis,`` Genesis said in a statement.

In the study, 241 patients with moderate to severe psoriasis were randomised four groups -- with one used as a control and the three other. Individual groups (approximately 60 patients) were then treated with one of three PVAC doses (two, 15 or 50 micrograms).

The study found that 23 percent of those in the middle dose group (15 micrograms) saw a 50 percent or greater reduction in psoriasis, as measured by the psoriasis area and severity index (PASI), after 12 weeks.

``The 15-microgram dose was the same dose administered in Phase I PVAC treatment trials conducted in the Philippines that had previously suggested clinical benefit,`` Genesis said.

PVAC is a derivative of mycobacterium vaccae developed by Genesis in collaboration with Corixa.

Genesis said around 2.6 percent of the U.S. population, seven million people, are affected by psoriasis -- which occurs when new skin cells grow too rapidly resulting in inflamed, scaly skin lesions.

[toller]

Press Release
Corixa, Medicis and Genesis Announce Phase II Trial Evidence of Clinical Benefit and Safety At 15-Microgram Dose
SEATTLE & SCOTTSDALE, Ariz. & AUCKLAND, New Zealand-- (BW HealthWire)--Feb. 14, 2001--Corixa Corporation (Nasdaq:CRXA - news), a research- and development-based biotechnology company, Medicis Pharmaceutical Corporation (NYSE:MRX - news) and Genesis Research and Development of New Zealand today announced preliminary U.S. Phase II clinical trial results on Corixa`s immunotherapeutic psoriasis treatment, PVAC(TM). Analysis of the results of a four-arm, randomized, double-blinded, controlled study in the United States, suggests that PVAC therapy at a dose of 15 micrograms per injection provides appreciable clinical benefit in patients with moderate to severe psoriasis.

Corixa announced in August 2000 that enrollment of 241 patients in its U.S. Phase II PVAC treatment study had been completed. In this four-arm study, patients with moderate to severe psoriasis were randomized to one of four groups. Individual groups (approximately 60 patients) were then treated with either control (CANDIN, a local irritant which produces a hypersensitivity reaction in most patients) or one of three different dosages of PVAC treatment (2, 15 or 50 micrograms). Efficacy endpoints-- improvements in disease severity as assessed by decrease in psoriasis area and severity index (PASI) score-- were measured every three weeks for twelve weeks following the first administration of study treatment. In this Phase II trial, PVAC or control were given via intradermal injection on day 0 and day 21 of the study. This was the same route of administration and dosing schedule that was used in early Phase I PVAC studies conducted in the Philippines.

Evidence of Clinical Benefit

The Phase II study, conducted in a randomized and controlled setting, was designed to provide safety data and to determine an optimal dose for future efficacy studies. However, clinical efficacy assessed in the middle dose group (15 micrograms), as compared to the CANDIN control group, approached statistical significance (p=.08) when the efficacy endpoint was at least a 50 percent reduction in PASI score. The companies have concluded that patients receiving the 15-microgram dose had more impressive results than patients receiving other doses. Among the 60 patients in the 15-microgram-dose group, 23 percent had a 50 percent or greater reduction in PASI score at 12 weeks.

Of the 21 patients in this dose group who had not been treated previously with any form of ultraviolet light, methotrexate or cyclosporin, 43 percent had a 50 percent or greater reduction in PASI score at 12 weeks. Methotrexate, cyclosporin and ultraviolet light therapies are modalities reserved for the most serious cases of psoriasis and likely affect the immune system for long time periods and perhaps permanently. The vast majority of psoriasis patients are not treated with these agents, according to a survey of physicians conducted by Market Measures, Inc. The 15-microgram dose was the same dose administered in Phase I PVAC treatment trials conducted in the Philippines that had previously suggested clinical benefit.

Moreover, further analysis indicates that the percentage of responders in the 15-microgram-dose group achieving either a 50 percent or 75 percent reduction in PASI score continued to increase with time and reached their highest levels at the 12 week observation point. The companies believe this observed increase in efficacy over time suggests that more patients might have been found to reach either a 50 percent or 75 percent improvement in disease severity had the observation point been later than 12 weeks from the first dose of PVAC. A later observation point was not measured because of the Phase II study design. Subsequent studies will likely include measurement points beyond 12 weeks.

Detailed analyses of patient responses at the 15-microgram dose confirmed the clinical efficacy of PVAC. For example, when a comparison was made of the best response (decrease in PASI score) observed at any observation point for patients in the 15-microgram-dose group was compared to the best response in the CANDIN control group, a statistically significant difference was observed favoring the 15-microgram dose group (p= 0.04).

In addition, the moderate and severe psoriasis patients treated in the U.S. Phase II trial had a significantly longer prior history of disease (median of 18 or more years) than did patients treated in the initial Phase I Philippines study (median of three years prior disease history). Moreover, the U.S. patient population studied in the Phase II trial had significant prior exposure to a variety of therapies for a duration that might interfere with or delay responses to an immunoregulatory product such as PVAC, including repetitive exposure to immunosuppressive therapies such as ultraviolet light irradiation, methotrexate and cylcosporin. As such, the U.S. Phase II study provided an extremely rigorous test in which to assess the clinical performance of PVAC.

Evidence of Safety

The benign safety profile of PVAC observed in Phase I investigation was again confirmed in the U.S. Phase II clinical trial. There were no moderate or severe systemic adverse reactions to PVAC administration, nor were there any differences in frequency of other systemic adverse events observed between any PVAC dose group, or between any PVAC dose group and the control group. The only adverse event with an increased incidence over the control group was the percentage of patients with injection site reactions in the 15- and 50-microgram dose groups compared to the site reactions induced by CANDIN. The majority of injection site reactions were mild to moderate.

``Based on the preliminary data disclosed today, we are quite encouraged that PVAC treatment continues to demonstrate clinical benefit in a controlled setting,`` said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. ``The U.S. Phase II study has demonstrated clinical activity at the same dose of 15 micrograms per injection that was evaluated in the Philippines. Corixa and its partners, Medicis, Genesis Research and Development, and Zenyaku Kogyo, are developing plans for the next major clinical study of PVAC. Such a trial will likely be a randomized, blinded and controlled study in which different groups of patients would receive 15 micrograms of PVAC in possibly two or three different dosing schedules. Based on the results to date, clinical benefit may be assessed at multiple time points following administration for a longer period of time. Studies may also compare patients with different prior exposure to immunosuppressive therapy.

Gillis added, ``Given the speed with which the current study was accrued and completed, we are hoping to construct a statistical plan very shortly for the next study that the FDA may consider supportive for product registration. In the interim, we will gather additional data from an on-going 180 patient, randomized study in Brazil. In this trial of moderate and severe psoriasis patients, patients are being randomized to two-dose therapy with either saline, or 15 or 50 micrograms of PVAC treatment.``

Jonah Shacknai, chairman and chief executive officer of Medicis added, ``We are very encouraged by the results of this Phase II study. We have improved greatly our understanding of PVAC`s appropriate dosing regimen, the objective of this phase of development. We believe PVAC demonstrated an impressive effect on some of the toughest psoriasis cases, with a clear reinforcement of the agent`s attractive safety profile. If further trials continue to show strong efficacy and safety results, we believe that we that will have an excellent commercial platform for PVAC.``

``We are heartened by the consistent safety profile displayed by PVAC treatment and the strong parallels in the dose regimen and efficacy that have come from the Philippines and U.S. Phase II studies,`` said Jim Watson, chief executive of Genesis. ``If our ongoing and further studies continue to show strong efficacy results, we believe PVAC has every prospect of being an excellent first-line therapeutic for psoriasis.``

On August 15, 2000, Corixa announced it entered into a multi-year development, commercialization and license agreement with Medicis for the commercialization of PVAC in the United States and Canada. On August 19, 1999, Corixa announced a multi-year license, research and development agreement with Zenyaku Kogyo Co. Ltd., providing the company with exclusive rights to PVAC in Japan. PVAC treatment is a derivative of Mycobacterium vaccae (M.vaccae) developed by Corixa, in collaboration with New Zealand-based Genesis Research and Development Corporation Limited.

Psoriasis Market Information

According to the National Psoriasis Foundation, psoriasis is a chronic skin disease affecting more than seven million Americans, or about 2.6 percent of the U.S. population. Psoriasis occurs when new skin cells grow too rapidly, resulting in inflamed, scaly skin lesions. It is estimated that approximately 30 percent of the patient population suffer from a moderate to severe form of the disease. About 150,000 to 260,000 new cases of psoriasis are diagnosed each year. Annual outpatient costs for treating psoriasis are currently estimated at approximately $1.6 to $3.2 billion. Although the cause of psoriasis is unknown, researchers believe the increased activation, adhesion and passage of T-cells to the skin contributes to the inflammation and abnormal skin cell proliferation. Most current psoriasis therapies are palliative in nature and provide temporary patient benefit, or have significant side effects.

About Corixa

Corixa is a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary vaccine components on a standalone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, Bexxar(TM), a monoclonal antibody conjugated to a radioisotope.

The company partners with numerous developers and marketers of pharmaceuticals and diagnostics, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. and South San Francisco, Calif. For more information, please visit Corixa`s website at www.corixa.com or call the company`s investor relations information line at 1.877.4CORIXA or 1.877.426.7492.

About Medicis

Medicis is the leading independent pharmaceutical company in the United States focusing primarily on the treatment of dermatological conditions. Medicis develops and markets leading products for major segments within dermatology including acne, fungal infections, psoriasis, eczema, rosacea, seborrheic dermatitis, head lice and cosmesis (improvement in the texture and appearance of skin). Primary products include the prescription brands DYNACIN® (minocycline HCl), TRIAZ® (benzoyl peroxide), LUSTRA® (hydroquinone), LOPROX® (ciclopirox), OVIDE® (malathion), PLEXION(TM) (sodium sulfacetamide/sulfur), LIDEX® (fluocinonide), SYNALAR® (fluocinolone acetonide), TOPICORT® (desoximetasone), NOVACET® (sodium sulfacetamide/sulfur) and A/T/S® (erythromycin); the over-the-counter brand ESOTERICA®; and BUPHENYL(TM) (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder. Full prescribing information for any Medicis prescription product is available by contacting the Company.

About Genesis

Genesis is a New Zealand-based biotechnology committed to the building of a broad genomic platform for the development of innovative products for human health and agriculture. Genesis uses partnerships with industry leaders to target products that have global market potential through the gene mining of its extensive microbe, plant and mammalian EST databases. In addition to its collaboration with Corixa in the development of PVAC, Genesis has two other programs in human clinical development, five additional programs in pre-clinical development and two programs in plant biotechnology. Genesis was founded in 1994 in Auckland, New Zealand. For more information, please visit the Genesis website at www.genesis.co.nz.

Forward-Looking Statements

Except for the historical information presented, certain matters discussed in this press release are forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the time the statements are made. They are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Factors that could affect the companies` actual results include, but are not limited to failure of PVAC treatment to prove safe or efficacious in patients, uncertainty of future financial results and other risks detailed from time to time in the companies` public disclosure filings with the U.S. Securities and Exchange Commission (SEC) including Corixa`s ``Factors Affecting Our Operating Results, Our Business and Our Stock Price,`` described in Corixa`s Quarterly Report on Form 10-Q/A filed on November 7, 2000, Corixa`s Registration Statement on Form S-4/A filed on November 17, 2000, Medicis Pharmaceutical`s Annual Report on Form 10-K for the fiscal year ended June 30, 2000 and the Quarterly Report on Form 10-Q from Medicis for the quarterly period ended September 30, 2000. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and the companies disclaim any intent or obligation to update these forward-looking statements. Copies of the companies` public disclosure filings with the SEC are available from each company`s investor relations department or at the companies` respective web sites, www.corixa.com and www.medicis.com.

NOTE: CANDIN is a Candida albicans skin test antigen manufactured by Allermed Laboratories Inc., San Diego, CA.


--------------------------------------------------------------------------------
Contact:

Corixa Corp.
Jim DeNike, 206/754-5716
[e-mail]
or
Genesis Research and Development Corp.
J.D. Watson, 011.64.9.3735600
[e-mail]
or
Medicis Pharmaceutical Corp.
Libby Ivy, 602/808-3854
[e-mail]
or
Botica Conroy and Associates
Allan Botica, 011.64.9.3033862
021.400500
[e-mail]

[toller]

die vielen Meldungen im zusammenhang mit corixa in den letzten tagen kann man gar nicht alle posten...daher verweise ich einfach mal auf

http://finance.yahoo.com

nach CRXA suchen. jede menge artikel.


von gestern:
Downgrade:
Prudential Corixa Corp CRXA downgrade from Strong Buy
to Hold

[toller]

gibts euch noch?

[toller]

uups, FDA fordert bei Bexxar erneut neue Daten an....schade eigentlich!!!!

[Grossmeister M]

Ich nehme an dass die deshalb um über 20% absaufen.
Shit dass ich bei 15E gekauft habe.
Wenn die weiter so fallen, haben die bald mehr Cash als Marktkap.

[Sixi]

Bexxar hat dem Wert nichts geholfen. Shit-Aktie. Intakter
Abwärtstrend, KZ 5 Euro in 6 Wochen. Schade.

[trendwatcher]

Lohnt jetzt ein Einstieg bei Corixa?

Niedriges Kursniveau und Top-Meldung (s.u.) ...

trendwatcher

__________________________________________________________


CORIXA DECIPHERS THE GENOME OF THE MAJOR ORGANISM RESPONSIBLE FOR ACNE, CLEARING THE WAY FOR THE DEVELOPMENT OF NEW ACNE TREATMENTS AND VACCINES
Seattle, April 05, 2001 - Corixa Corporation (Nasdaq: CRXA), a developer of immunotherapeutics, today announced it has decoded the genome of the major microbial agent involved in the development of human acne, Propionibacterium acnes (P. acnes). Acne is the most commonly diagnosed skin disorder in the United States.
In 2000, Corixa contracted with Paris-based Genset SA to sequence the P. acnes genome. Subsequently, Genset has determined the precise order of approximately 2.8 million base pairs of the P. acnes genome. Corixa plans to use this information in conjunction with its proprietary antigen discovery technology to accelerate development of potential new acne treatments and vaccines.

To date, Corixa scientists have mapped and characterized over 150 P. acnes proteins. The Company has determined that more than 30 of these proteins are recognized as antigens by the immune systems of volunteers with a history of severe acne. The identification of multiple candidate antigens is an important first step in the design of a vaccine for acne. In addition to its use in vaccine development, Corixa believes that the genomic information can be used to identify targets for new anti-microbial drugs that may be less toxic and more effective than current acne drugs. A presentation of the company`s approaches in these areas of investigation is being made today at the World Vaccine Congress in Montreal, Quebec, by Dr. David Persing, M.D., Ph.D., vice president at Corixa.

"We are extremely pleased with the progress of this project, which represents only one of several programs within our extensive discovery pipeline," said Steven Gillis, Ph.D., chairman and chief executive officer at Corixa. "We believe that the combination of a proprietary genomic intellectual property position, Corixa`s innovative antigen discovery approaches and proprietary adjuvant and delivery technologies provides us with a significant jump start toward the development of a potential vaccine for acne. We look forward to our continued progress on this program."

About Acne

Acne is an inflammatory disorder of the skin`s oil glands (sebaceous glands) that results in plugged pores and outbreaks of lesions commonly referred to as pimples. Acne lesions usually occur on the face, neck, back, chest, and shoulders. Nearly 17 million people in the United States have acne, making it the most common skin disease in this country. Although acne is not a serious health threat, severe acne can lead to disfigurement and permanent scarring.

Acne lesions begin by the clogging of skin`s pores, or follicles, with oil and dead skin cells. The mixture of oil and cells allows the bacterium P. acnes (which normally lives in skin pores) to grow to large numbers in the plugged follicles. In cases of acne, plugged follicles burst, spilling their contents into the surrounding tissue. Lesions or pimples develop because components of P. acnes that are present in the follicle contents, promote inflammation. Current methods of treatment for acne consist of antibiotics, topical peroxides and retinoic acid derivatives (retinoids) that are largely aimed at controlling P. acnes growth and preventing the plugging of skin pores. A vaccine for P. acnes, if proven effective at suppressing P. acnes growth or reducing its inflammatory effects, may be less toxic and provide more lasting benefit than current therapies. Such a vaccine could become an important part of the overall management strategy for acne.

More information on acne is available at the NIH website: http://www.nih.gov/niams/healthinfo/acne/acne.htm.

About Corixa

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. Corixa currently has 16 programs in clinical development and 22 programs in preclinical development, including its most advanced product candidate, Bexxar™, a monoclonal antibody conjugated to a radioisotope.

The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are Powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Montana and Redwood City, California and South San Francisco, California. For more information, please visit Corixa`s website at www.corixa.com or call the company`s investor relations information line at 1.877.4CORIXA or 1.877.426.7492.

[Sixi]

Schei... die Aktie ist ein typischer Pleite o. Übernahmekandidat. Ich kann jeden nur warnen so eine F...Aktie. Der Chart sagt alles.
zu kaufen. Einstieg ab 1 Euro wieder interessant.
F...Aktie .

[toller]

unsere Corixa/coulter werden sich erholen. seit dem tief von knapp 7.45 Euro Anfang April nun schon wieder bei 20 Euro. sicher gibt der Euro verfall nochmal einen kleinen Prozentpunkt drauf, aber ansonsten macht sich jetzt der vorteil der übernahme durch corixa bemerkbar. die haben mehr in der pipeline als nur Bexxar, welches ja leider erneut abgelehnt wurde. bin damals nach der ersten ablehnung im Mai letzten jahres eingestiegen bei 23euro. und bexxar wird kommen, wenn die FDA mal ruhe gibt mit ihrem Zweifel und dem ganzen Kampf um "wen lassen wir jetzt zuerst zu? Bexxar oder Zevalin" (konkurrenzprodukt von IDEC Pharm.)

gruesse an alle die bis jetzt dabeigeblieben sind.

[rainrain]

ca. 350% in 2 Monaten!!



beste Grüße an meinen Freund toller und alle restlichen CRXAnleger (gibt es noch welche hier??)

rainrain

[toller]

Monday June 11, 4:22 pm Eastern Time
Press Release
Corixa Receives $3.5 Million Contract From SPAWAR Systems Center San Diego for a DARPA Sponsored Program to Develop a Novel Defense Against Biological Warfare Agents
SEATTLE--(BW HealthWire)--June 11, 2001--Corixa Corporation (Nasdaq:CRXA - news), a developer of immunotherapeutics, today announced it has been awarded a $3.5 million, two year contract from the Space and Naval Warfare (SPAWAR) Systems Center San Diego for a Defense Advanced Research Projects Agency (DARPA) sponsored program to develop methods of enhancing immune responses to infectious diseases, including agents of biological warfare.

As a result, Corixa will conduct preclinical testing of its proprietary portfolio of synthetic lipid A-like immunomodulatory agents, or AGP(s), to enhance innate immune responses. These drugs act on a newly recognized family of receptors, called Toll-like receptors, to generate protective immunity to a wide variety of infectious agents. Certain Toll-like receptors are present in the upper airways and stimulation of these receptors may induce the immune system to prevent infections of various types, especially those transmitted by inhalation. Corixa scientists have already demonstrated that administration of some of these potential drugs by the intranasal route is highly efficient at protecting against influenza virus infection in experimental animal models.

``We are pleased to have been selected as a recipient of a DARPA contract,`` said David H. Persing, M.D., Ph.D, vice president of antigen discovery and diagnostics development at Corixa and principal investigator on the contract. ``This project represents the latest development-stage application of Corixa`s proprietary family of synthetic immunomodulators for the treatment and prevention of infectious disease. We are pleased that DARPA recognizes the potential value of these compounds for eventual military and civilian use. We look forward to further elucidation of the role that AGP(s) might play in stimulating innate immunity.``

[toller]

falls noch jemand von euch da ist, corixa hats ja mal wieder nett nach unten gezogen. aber genauso gut geht´s nach oben. die haben eine gute pipeline.

grüße

Among the day`s biggest percentage gainers was Corixa`s stock, which rose $1.39, or 13 percent, to $12.30. Analyst Mark Monane at Needham & Co. said a Corixa-sponsored conference this week highlighted the promise of medications the company is developing, including experimental cancer treatment Bexxar.

Back in March, Corixa (CRXA: news, chart, profile) shares plunged after the Seattle-based company said the FDA had asked for more data about Bexxar. Such requests typically significantly delay marketing clearance for a product. But Monane said he believes Bexxar will ultimately win FDA approval and be on the market in late 2002. Monane said he`s also optimistic about Corixa`s other potential products, including a skin cancer treatment.

"Corixa has the scientific and management expertise to bring drugs to market," Monane wrote in a note to clients.